MYQORZO approved and generating revenue across US, EU, and China; label expansion to non-obstructive HCM hinges on Nov 2026 FDA decision

Bull

FDA approves the sNDA on or before the PDUFA date, granting MYQORZO a label in symptomatic non-obstructive HCM (nHCM) — a population with no approved pharmacotherapy — validated by ACACIA-HCM's dual primary endpoint success (statistically significant improvements in KCCQ Clinical Summary Score and peak VO2 at Week 36). Approval would open a second, distinct HCM market, accelerate revenue growth beyond the oHCM launch trajectory, and position MYQORZO as the first-and-only approved therapy across both HCM subtypes.

Bear

FDA issues a Complete Response Letter citing concerns about the magnitude of clinical benefit in nHCM, requesting additional data on the functional endpoint or raising labeling questions about the nHCM patient population's definition and identification. The most plausible failure modes are a benefit-risk debate in a population without outflow tract obstruction — where the disease mechanism is less well-defined — or a request for longer-term outcomes data before granting approval, delaying the label expansion by one or more years.